A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Abdel-Mageed, Agrawal, Aiyar, Alahari., Andersson
Asim B. Abdel-Mageed, D.V.M., Ph.D.

Associate Professor of Urology, Adjunct Associate Professor of Pharmacology
Director of Molecular Oncology Research Laboratories
TCC Program Member
amageed@tulane.edu
Faculty listing on Urology website
Curriculum Vitae [PDF] (see also Help with PDF documents)
(504) 988-3634, (504) 988-5059 fax
1430 Tulane Ave., Box SL-42, New Orleans, LA 70112-2699



Biographical Narrative:

Dr. Abdel-Mageed received his D.V.M. from the University of Khartoum, Sudan, in 1983. He was a veterinary practitioner and a faculty member of the Department of Medicine, Pharmacology and Toxicology at the University of Khartoum until 1987. Dr. Abdel-Mageed obtained M.S. (1989) and Ph.D. (1993) degrees in molecular physiology/toxicology at Kansas State University before joining Tulane as a postdoctoral fellow in the Department of Pharmacology with Dr. Krishna Agrawal in 1994. He became a research instructor of pharmacology in 1996, continuing his training in molecular cancer pharmacology. He studied genes associated with breast cancer cell growth and their interaction with nuclear transcription factors to mediate mitogenic responses. In 1997, Dr. Abdel-Mageed joined the faculty as an Assistant Professor in the Department of Urology and adjunct Assistant Professor of Pharmacology. He is founding director of the Molecular Oncology Research Laboratories in the Department of Urology. Dr. Abdel-Mageed has over 25 peer-reviewed publications and has served on several DOD grant review panels. Dr. Abdel-Mageed's laboratory primarily focuses on basic research into the cellular and molecular aspects of urologic diseases, with particular attention given to prostate and bladder cancer. The laboratory has a special interest in tumor cell invasion, metastasis, and disease progression. Molecular biology, genetics, cell biology, and biochemical techniques, as well as studies involving transgenic TRAMP mouse model and in situ analysis of human tissues, are routinely employed to address questions concerning these issues. One area of major interest to Dr. Abdel-Mageed is the role of metallothionein in prostate cancer progression, with special emphasis on cell proliferation using antisense technology and on expression of invasion, angiogenesis and metastasis-related genes using in vitro and in vivo xenograft model systems. He is also examining their expression profile in situ to evaluate their correlation with tumor grade and their potential use as biomarkers for disease progression. More recently, his laboratory has been conducting studies pertaining to isolation and characterization of in vivo differentially expressed genes of prostate cancer as they relate to race, age, and tumor grade using state-of-the-art laser capture microdissection, suppressive subtractive hybridization and DNA microarray technology. Analysis of the expression and function of these genes should allow for a more in depth understanding of the processes controlling prostate cancer cell growth, invasion, and metastasis. Dr. Abdel-Mageed's research interests also include dissection of molecular mechanisms and signaling pathways associated with chemo/radioresistance of prostate cancer. Using a super-repressor I kappa B adenoviral delivery approach, his laboratory is conducting experiments to evaluate the role of inhibiting the activation of the nuclear factor NF-kappa B in enhancing radio/chemosensitization and apoptosis of prostate cancer cells.


Selected Publications:

Back to the top

Krishna C. Agrawal, Ph.D.

Chairman and Regents Professor of Pharmacology
TCC Program Member
agrawal@tulane.edu
Homepage on Pharmacology website:
http://www.som.tulane.edu/departments/pharmacology/Faculty/agrawal.html
(504) 988-5444, (504) 988-1846 fax
1430 Tulane Ave., Box SL-83, New Orleans, LA 70112-2699



Biographical Narrative:

Dr. Agrawal received his Ph.D. in 1965 from the University of Florida. His research interests include mechanisms of drug-induced toxicities, biomarkers, protection of normal tissues from genotoxic agents, growth control, and inhibition of HIV replication.


Selected Publications:

Back to the top

Aiyar, Ashok A.
Associate Professor

Original research:

  • Cobrinik, D., Aiyar, A., Ge, Z., Katzman, M., Huang, H., and Leis, J. Overlapping retrovirus U5 sequence elements are required for efficient integration and initiation of reverse transcription. J. Virol., 65: 3864-3872, 1991.
  • Aiyar, A., Cobrinik, D., Ge, Z., Kung, H.-J., and Leis, J. Interaction between retroviral U5 RNA and the TC loop of the tRNATrp primer is required for efficient initiation of reverse transcription. J. Virol., 66: 2464-2472, 1992.
  • Aiyar, A., and Leis, J. Modification of the mega-primer method of mutagenesis - improved amplification of the final product. Biotechniques, 14: 366-367, 1993.
  • Aiyar, A., Ge, Z., and Leis, J. A specific orientation of RNA secondary structures is required for initiation of reverse transcription. J. Virol. 68: 611-618, 1994.
  • Aiyar, A., Hindmarsh, P., Skalka, A.M., and Leis, J. Concerted integration of linear retroviral DNA by the avian sarcoma virus integrase in vitro: Dependence on both long terminal repeat termini. J. Virol. 70: 3571-3580, 1996.
  • Aiyar, A., Tyree, C., and Sugden, B. The plasmid replicon of Epstein-Barr virus consists of multiple cis-acting elements that facilitate DNA synthesis by the cell and a viral maintenance element. EMBO J. 17: 6394-6403, 1998.
  • Aiyar, A., and Sugden, B. Fusions between EBNA-1 of EBV and the large T-antigen of SV40 replicate their cognate origins. J. Biol. Chem. 273: 33073-33081, 1998.
  • Haan, K.M., Aiyar, A., and Longnecker, R. Establishment of latent Epstein-Barr virus infection and stable episomal maintenance in murine B-cell lines. J. Virol. 75: 3016-3020, 2001.
  • Kikonyogo, A., Bouamr, F., Vana, M.L., Xiang, Y., Aiyar. A., Carter, C., and Leis, J. Proteins-Related to the Nedd4 Family of Ubiquitin Protein Ligases Interact with the L Domain of Rous Sarcoma Virus and Are Required For Gag Budding from Cells. Proc. Natl. Acad. Sci. (USA), 98: 11199-11204, 2001.
  • Hebner, C., Lasanen, J., Battle S., and Aiyar, A. The spacing between adjacent binding sites in the family of repeats (FR) affects the functions of Epstein-Barr nuclear antigen 1 (EBNA1) in transcription activation and stable plasmid maintenance. Virology 311: 263-274, 2003.
    Sears, J., Kolman, J., Wahl, G.M., and Aiyar. A. Metaphase chromosome tethering is necessary for the DNA synthesis and maintenance of oriP plasmids but is insufficient for transcription activation by Epstein-Barr nuclear antigen 1 (EBNA1). J. Virol., 77: 11767-11780, 2003.
  • Sears, J., Ujihara, M., Wong, S., Ott, C., Middeldorp, J. and Aiyar, A. The amino-terminus of Epstein-Barr nuclear antigen 1 (EBNA1) contains AT-hooks that mediate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. J. Virol. 78: 11487-11505, 2004.
  • Chen, Y., Miller, W.M., Aiyar. A. The transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio. J. Am. Chem. Soc. (Biotech. Progres. section) Biotech. Progres. 21: 274-282, 2005.
  • Norseen, J., Thomae, A., Sridharan, V., Aiyar, A., Schepers, A., and Lieberman, P.M. RNA-dependent rercruitment of the origin recognition complex. EMBO J. 27:3024-2035, 2008.
  • Chen, Y., Aiyar, A., and Miller, W.M. Cholesterol supplementation during production increases the infectivity of retroviral and lentiviral vectors pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G). Biochem. Engg. J. (accepted 12/11/2008).
  • Singh, G., Aras, S., Zea, AH., Koochekpour, S., and Aiyar, A. Optimal transactivation by Epstein-Barr nuclear antigen 1 requires UR1 and ATH1 domains. J. Virol. 83:4227-4235, 2009.
  • Aras, A., Singh, G., Porreta, C., Johnston, K., Foster, T., Aiyar, A. Zinc coordination is required for and regulates transcription activation by Epstein-Barr nuclear antigen 1. PLoS Pathogens (accepted 4/6/2009).

Book chapters/reviews:

  • Leis, J., Aiyar, A., and Cobrinik, D. Regulation of the initiation of reverse transcription. In: S. Goff and A.M. Skalka (Eds.) Reverse Transcriptase, pp. 33-47. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1993.
  • Aiyar, A., Xiang, Y., and Leis, J. Site-directed mutagenesis using overlap extension PCR. In: M. Trower (Ed.), Methods in Molecular Biology, Vol. 57, pp. 177-191. Totoua, NJ: Humana Press Inc., 1995.
  • Leis, J., and Aiyar, A. Retrovirus reverse transcription and integration. In: K. W. Adolph (Ed.), Viral Gene Techniques, pp. 254-266. San Diego, CA: Academic Press Inc., 1995.
  • Aiyar, A. The use of Clustal W and Clustal X for multiple sequence alignment. In S. Misener and S. Krawetz (Eds.) Methods in Molecular Biology: Computer Analysis of Sequence Data, Vol. 132, pp. 221-242. Totoua, NJ: Humana Press Inc., 2000.

Back to the top

Suresh K. Alahari
Associate Professor

Positions and Employment

  • 1986-1989 Research Scholar, All India Institute of Medical Sciences, New Delhi, India.
  • 1990-1994 Research/Teaching Assistant, Department of Bioscience and Biotechnology, Drexel University, Philadelphia, PA
  • 1994-1998 Research Associate, University of North Carolina at Chapel Hill
  • 1998-2004 Assistant Professor, University of North Carolina at Chapel Hill
  • 2005 Visiting Faculty, University of Pennsylvania, Philadelphia, PA 19104
  • 2006 Visiting professor, Rockefeller University, New York, NY 10012
  • 2004- Associate Professor, Dept. of Biochemistry, LSU School of Medicine, New Orleans

Selected Publications:

  • Malter, J.S., Moolten, D.N., Alahari, S.K., Makni, H., Kant, J.A. and Kamoun, M. Detection of CD2 polymorphism chromosome 1 with EcoR1 (1990) Nucleic Acids Research, 18: 6465.
  • Rosenberg,G.H., Alahari, S.K. and Käufer, N.F. Prp4 from Schizosaccharomyces pombe a mutant deficient in pre-mRNA splicing isolated using genes containing artificial introns (1991) Mol. and Gen. Genetics, 226: 305-309
  • Alahari, S.K., Schmidt, H. and Käufer, N.F. The fission yeast prp4+ gene involved in pre-mRNA splicing codes for a serine/threonine kinase and is essential for growth (1993). Nucleic Acids Res. 21: 4079-4083.
  • Zerva,L., Cizman, B., Mehra, N.K., Alahari, S.K., Zmijewski, C.M., Kamoun, M.and Monos, D. Arginine at positions 13 or 70-71 of HLA-DRB1 alleles confer susceptibility to Tuberculoid Leprosy (1996) Journal of Experimental Medicine 183, 829-836
  • Alahari, S.K., Dean N.M., Fisher, M.H., Delong, R., Manoharan, M., Tivel, K.L., and Juliano, R.L.: Inhibition of expression of the multi-drug resistance associated P-glycoprotein by Phosphorothioate and cholesterol-conjugated phosphorothioate antisense oligonucleotides. (1996) Mol. Pharmacology, 50: 808-819.
  • DeLong, R., Stephenson, K., Loftus. T., Fisher, M., Alahari, S.K., and Juliano, R.L. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. (1997) J. Pharm. Sciences 86: 762-764.
  • Aplin, A., Howe, A., Alahari, S. K., and Juliano, R.L. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, IG-CAMS and selectins. (1998) Pharmacological Reviews 50: 197-263
  • Howe.A., Aplin, A., Alahari, S.K., and Juliano, R.L.. Integrin signaling and cell growth Control. (1998) Current Opinion in Cell Biology 10: 220-231.
  • Alahari, S.K., Delong, R., Fisher, M.H., Dean, N. M. Viliet, P and Juliano, R.L. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. (1998) J.Pharm.Exp. Therapeutics 286:419-428.
  • Juliano, R.L., Alahari, S.K., Yoo, H., Kole, R., and Cho, M. Antisense Pharmacodynamics: Critical issues in the transport & delivery of antisense oligonucleotides. (1999) Pharmaceutical Research 16: 494-502.
  • Hughes, J. A., Astriab,A., Yoo, H., Alahari, S.K., Liang, E., Sergueev, D., Shaw, B. and Juliano, R.L.: In Vitro Transport and delivery of oligonucleotides. Methods in Enzymology (1999) 313:343-359.
  • DeLong, R.K., Hoon, Y., Alahari, S.K., Fisher, M., Short, S.M., Kole, R and Juliano, R. L.: Novel cationic amphiphiles as delivery reagents for antisense oligonucleotides. (1999) Nucleic Acids Research 27:3334-3341.
  • Shock, D.D., Naik, U.P., Brittain, J.E., Alahari, S. K., Sondek, J., and Parise, L.V.: Calcium-dependent properties of CIB binding to the integrin alphaIIb cytoplasmic domain and translocation to the platelet cytoskeleton (1999) Biochemical Journal 342: 729-735.
  • R.L. Juliano, Aplin, A.E., Howe, A., Short, S., Lee, JW, and Alahari, S.K.: Methods for study of integrin regulation of receptor tyrosine kinase and G protein coupled receptor signaling to MAP kinases (2001) Methods In Enzymology 333:151-163.
  • Alahari, S.K., Lee, J.L., and Juliano, R.L.: NISCHARIN, a novel protein that interacts with integrin 5 subunit, and inhibits cell migration (2000). J. Cell Biology 151: 1141-1154.
  • Alahari, S.K.,: Mapping of the gene for Nischarin, a novel integrin binding protein, to chromosome 3 by fluorescence in situ hybridization (2001). Intl. J. Human Genetics 1: 271-274.
  • Alahari, S.K., Reddig, P., Juliano, R.L. Biological aspects of signal transduction by cell adhesion receptors (2002). Int. J. Cytology 220: 145-174.
  • Alahari, S.K.: Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK (2003). Exp. Cell Res 288: 415-424.
  • Alahari, S.K. and H. Nasrallah : A Membrane proximal region of 5 integrin is essential for its interaction with Nischarin (2004) Biochemical Journal 377: 449-457.
  • Alahari, S.K., Reddig, P., Juliano, R.L. The integrin binding protein Nischarin regulates cell migration by inhibiting PAK (2004) EMBO J 23: 2777-2788.
  • Juliano, R.L., Reddig, P., Alahari, S., Edin, M., Howe, A and Aplin, A. Integrin regulation of cell signaling and motility (2004) Biochem Soc Trans. 200432: 443-446.
  • Ding, Y and Alahari, S.K. Nischarin inhibits LIMK to regulate Cofilin phosphorylation and Cell Invasion (2007) Journal of Cell Biology (Submitted).

Back to the top

Hans C. Andersson, M.D.
Associate Professor of Human Genetics
TCC Contributing Member
handers@tulane.edu
Homepage: http://www.som.tulane.edu/departments/human_genetics/faculty/andersson.html
(504) 988-5229, (504) 988-7691 fax
1430 Tulane Ave., Box SL-31, New Orleans, LA 70112-2699

Dr. Andersson received his B.S. in Music and Psychology from Tulane in 1978 and received his M.D. from Tulane in 1984. He completed his residency in Pediatrics at the Tulane School of Medicine in 1987. Dr. Andersson also did a fellowship from 1987-1991 at the Hayward Genetics Center and was promoted to Associate Professor in 2000. Dr. Andersson's research focuses on lysosomal storage, inborn errors and medical genetic test reporting.


Selected Publications:
  • Andersson HC, Kohn AD, Gahl WA, Kohn LD. Photoaffinity labeling of lysosomal membrane proteins with [125I]diiodotyrosine, a system h ligand. Biochem Mol Med Jun; 55(1):71-3 (1995)
  • Napoleone RM, Varela M, Andersson HC. Complex congenital heart malformations in mosaic tetrasomy 8p: a case report and literature report. Am J Med Genet 73(3): 330-3. (1997)
  • Andersson HC, Shapira E. Biochemical and clinical response to hydroxocobalamin versus cyanocobalamin treatment in cblC - methylmalonicacidemia/homocystinuira. J Ped 132(1): 121-4. (1998)
  • Andersson HC, Frentz J, Martinez JE, Tuck-Muller CM, Bellizaire J. Adrenal Insufficiency inSmith-Lemli-Opitz Syndrome. Am J Med Genet 82: 382-4. (1999)
  • Andersson HC, Marble M, Shapira E. Long-term outcome in combined methylmalonic acidemia andhomocystinuria (cblC). Gen In Med 1: 146-150. (1999)
  • Charrow J, Grabowski G, Andersson HC, Kaplan P, Kolodny EH, et al. The Gaucher registry: demographics and disease characteristics of 1,698 patients with Gaucher Disease. Arch Intern Med 160: 2835-2843. (2000)
  • Krousel-Wood M, Andersson HC, Rice J, Jackson KE, Rosner E, Lubin IM. Physicians' perceived usefulness of and satisfaction with test reports for cystic fibrosis (Delta-F 508) and Factor V Leiden. Gen in Med 5(3): 166-171 (2003)
  • Charrow J, Grabowski G, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Prakash-Cheng A, Rosenbloom B, Scott RC, Wappner RS, Weinreb NJ. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: Consensus monitoring. J Pediatr 144(1): 112-120 (2004)


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Back to the top

 

Our Partners